Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History WVE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics WVE

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Wave Life Sciences Ltd

WVE
Current price
7.84 USD +0.17 USD (+2.22%)
Last closed 7.70 USD
ISIN USY953081053
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 276 873 216 USD
Yield for 12 month +30.88 %
1Y
3Y
5Y
10Y
15Y
WVE
21.11.2021 - 28.11.2021

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. Address: Marina One East Tower, Singapore, Singapore, 018936

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

20.38 USD

P/E Ratio

Dividend Yield

Financials WVE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures WVE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+108 302 000 USD

Last Year

+113 305 000 USD

Current Quarter

+9 175 000 USD

Last Quarter

+83 748 000 USD

Current Year

+108 302 000 USD

Last Year

+104 099 000 USD

Current Quarter

+9 175 000 USD

Last Quarter

+83 748 000 USD
EBITDA -122 020 000 USD
Operating Margin TTM -542.82 %
Price to Earnings
Return On Assets TTM -30.02 %
PEG Ratio
Return On Equity TTM -105.50 %
Wall Street Target Price 20.38 USD
Revenue TTM 104 939 000 USD
Book Value 1.12 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -26.80 %
Dividend Yield
Gross Profit TTM -61 918 000 USD
Earnings per share -0.75 USD
Diluted Eps TTM -0.75 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -107.04 %

Stock Valuation WVE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 9.32
Price Sales TTM 12.17
Enterprise Value EBITDA -10.12
Price Book MRQ 6.97

Technical Indicators WVE

For 52 Weeks

5.04 USD 16.74 USD
50 Day MA 6.78 USD
Shares Short Prior Month 14 881 762
200 Day MA 10.11 USD
Short Ratio 14.07
Shares Short 15 801 693
Short Percent 13.05 %